THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO
596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF
THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED
("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA
A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS
NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
19
November 2024
Abingdon Health Plc
("Abingdon" or the
"Company")
Annual General Meeting
Statement
At today's Annual General Meeting of Abingdon
(AIM:ABDX), a leading international
lateral flow contract development and manufacturing
organisation, Dr Chris Hand, the Chairman of Abingdon, will make
the following statement:
"We are pleased to report that the Group, as
enlarged by its recent acquisitions, and the establishment of its
US presence in Madision, Wisconsin, USA, expects to see
continued revenue growth. Although it is early in the year and
there are therefore various meaningful new contracts still to
be won, typically in the second half of the financial year, the
Board remains confident of solid progress for FY2025."
Enquiries
|
Abingdon Health plc
|
www.abingdonhealth.com/investors/
|
|
Chris
Yates, Chief Executive
Officer
|
Via
Walbrook PR
|
|
Chris Hand, Executive Chairman
|
|
|
|
|
|
Zeus (Sole Broker and Nominated Adviser)
|
Tel:
+44 (0) 20 3829 5000
|
|
Chris Fielding / Alexandra
Campbell-Harris (Corporate Finance)
|
|
|
Fraser Marshall (Corporate
Broking)
|
|
|
|
|
|
Walbrook
PR (Media & Investor Relations)
|
Tel: +44 (0)20 7933
8780 or abingdon@walbrookpr.com
|
|
Paul McManus / Alice
Woodings
|
Mob: +44 (0)7980 541
893 / +44 (0)7407 804 654
|
|
Phillip Marriage
|
+44 (0)7867 984
082
|
|
|
| |
The person responsible for arranging
the release of this announcement on behalf of the Company is Chris
Yates, Chief Executive Officer of the Company.
About Abingdon Health plc
Abingdon Health is a leading
med-tech contract service provider offering its services to an
international customer base.
The Group's CDMO
division offers lateral flow product
development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays
or transfer existing laboratory-based assays to a lateral flow
format. Abingdon Health's CDMO division has the internal
capabilities to take lateral flow projects, in areas such as
infectious disease and clinical testing, including companion
diagnostics, animal health and environmental testing, from initial
concept through to routine and large-scale manufacturing; from
"idea to commercial success".
Abingdon's regulatory services
companies, Compliance Solutions
(Life Sciences) and IVDeology,
provide a broad range of regulatory services to the in vitro
diagnostic and wider medical device industry, to support customers
in bringing products to market across a range of territories
including the USA, EU and the UK. Our consultancy services range
from design, implementation and maintenance of quality management
systems, preparation of technical files for regulatory approvals,
part-time and interim management support, auditing both internal
and external, management reviews and presentations, training and
mentoring.
Abingdon Health's Abingdon Simply
Test range of self-tests is an e-commerce platform that offers a
range of self-tests to empowers consumers to manage their own
health and wellbeing. The Abingdon Simply
Test e-commerce site offers consumers a range of information to
support them in making informed decisions on the tests available.
In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The
Abingdon Simply Test range is also sold through international
distributors and through other channels in the UK and Ireland, such
as pharmacy chains.
Founded in 2008, Abingdon
Health is headquartered in York, England.
For more information
visit: www.abingdonhealth.com
